-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhonghui Bio-B (02627) achieved an increase in revenue and net profit for the third quarter compared to the same period last year

Zhitongcaijing·11/17/2026 10:25:08
Listen to the news

According to the Zhitong Finance App, Zhonghui Bio-B (02627) announced that the Group achieved revenue of about RMB 322 million in the third quarter of 2026, an increase of about 3.5% over the same period last year; net profit was about RMB 59 million, an increase of about 15.5% over the same period last year.

The board of directors believes that the Group's revenue and net profit in the third quarter of 2026 both increased compared to the same period last year. The increase in net profit was significant, mainly due to the following factors: the Group's trivalent influenza virus subunit vaccine production batch and production increased in the third quarter of 2026 compared to the same period last year, and capacity utilization increased; in the third quarter of 2026, the Group continued to optimize internal management and streamline operations, and management expenses decreased compared to the same period last year; and with the optimization of the pace of R&D investment, R&D expenses for the third quarter of 2026 decreased compared to the same period last year; the Group reduced R&D expenses for the third quarter of 2026 compared to the same period last year; The revenue increase in the third quarter of 2026 was relatively moderate, mainly due to the following factors: starting in 2026, the value-added tax levy rate applicable to the Group's products was raised from 3% to 13%, leading to a slow increase in product unit sales revenue in the third quarter of 2026; and the unit sales price of the trivalent influenza virus subunit vaccine was about 7% lower than the quadrivalent influenza virus subunit vaccine. As the sales share of trivalent influenza virus subunit vaccine increased in the third quarter of 2026, the overall average sales unit price fell below the sales increase.

In the third quarter of 2026, the production, supply and batch issuance of the company's influenza virus subunit vaccine continued to advance in an orderly manner, and the supply of products was stable. In terms of production, after obtaining a commercial license for the trivalent influenza virus subunit vaccine in early 2026, the Group completed the production of finished vaccine products one after another. All batches passed internal quality inspections and submitted biological product batch issuance applications. As of September 30, 2026, the Group's influenza solution workshop and influenza preparation workshop have completed 100% and 93.9% of the annual production tasks, respectively. In terms of batch issuance, by the end of the third quarter in 2026, the Group had completed 30 batches of biological product batch issuance applications. Of these, 17 batches had obtained biological product batch issuance certificates before September 30, 2026. As of the date of this announcement, the remaining 13 batches have also obtained relevant certificates. In terms of quality management, the Group passed the Jiangsu Pharmaceutical Production Quality Management Specification (GMP) compliance inspection in the third quarter of 2026. As of the date of this announcement, the Group has passed a national vaccine inspection and two Jiangsu GMP compliance checks in 2026. In the fourth quarter of 2026, the Group will continue to meet market demand during the domestic influenza vaccination season and continue to promote the production, batch issuance and market distribution of trivalent influenza virus subunit vaccines. The Group's sufficient inventory and supply chain reserves will also ensure continued sales growth.

The board of directors is also pleased to announce that the company's “Commercialization of Class 1 New Drug Quadrivalent Influenza Virus Subunit Vaccine and Promotion and Application for Special Populations” project recently won the third prize of the Jiangsu Science and Technology Progress Award issued by the Jiangsu Provincial People's Government. The award is an official recognition of the technical maturity of the company's core products, ability to implement industrialization and application value for special groups. It also provides strong support for the company to further expand product market coverage and ensure supply quality.